Javitt DC, et al. - Experts aspired to identify measures with sufficient effect size and cross-site reliability to serve as glutamatergic target engagement biomarkers within early-phase clinical studies. They indicated robust effects of ketamine on pharmacoBOLD across sites, supporting its utility for definitive assessment of functional target engagement. Other measures were not sufficiently robust for use as cross-site target engagement measures, while being sensitive to ketamine effects.